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Abstract 
Background: There is little evidence whether a third arterial graft provides superior outcomes 
in comparison to the use of two arterial grafts in patients undergoing coronary artery bypass 
grafting (CABG).  A meta-analysis of all the propensity score matched (PSM) observational 
studies comparing the long-term outcomes of CABG with the use of two (2-ART) vs. three 
arterial (3-ART) grafts was performed. 
Methods: A literature search was conducted using MEDLINE, EMBASE, and Web of Science to 
identify relevant articles. Long-term mortality in the PSM populations was the primary 
endpoint. Secondary endpoints were in-hospital/30-day mortality for the PSM populations and 
long-term mortality for the unmatched populations. In the matched population, time-to-event 
outcome for long-term mortality was extracted as hazard ratios (HRs) along with their variance. 
Statistical pooling of survival (time-to-event) was performed according to a random effect 
model, computing risk estimates with 95% confidence intervals (CI). 
Results: A total of 8 PSM studies reporting on 10,287 matched patients (2-ART: 5346; 3-ART: 
4941) were selected for final comparison. The mean follow-up time ranged from 37.2 to 196.8 
months. The use of three arterial grafts was not statistically associated with early mortality (HR, 
0.93; 95% CI, 0.71-1.22; p= .62). The use of three arterial grafts was associated with statistically 
significantly lower hazard for late death (HR, 0.8; 95% CI, 0.75-0.87; p< .001), irrespective of sex 
and diabetic status. This result was qualitatively similar in the unmatched population (HR, 0.57; 
95% CI, 0.33-0.98; p= .04).  
 Conclusions: The use of a third arterial conduit in CABG patients is not associated with higher 
operative risk and is associated with superior long-term survival, irrespective of sex and diabetic 
status. 
  
 Clinical Perspective 
What is new?  
• The best available evidence suggests that the use of a second arterial graft at the time of 
coronary artery bypass operations leads to better postoperative survival.  
• However, less is known about the potential benefit of a third arterial conduit.  
• In the present analysis, we show that adding a third arterial conduit is not associated 
with an increased operative risk and is associated with improved long-term survival. 
 
What are the clinical implications?  
• Arterial grafts are largely underused for coronary artery bypass surgery.  
• By showing an association between improved survival and the use of a third arterial 
graft, these results support such a strategy and provide support for consideration of 
evaluation and confirmation in prospective randomized trials. 
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Introduction 1 
Current observational evidence strongly suggests that the use of two arterial grafts at the time 2 
of coronary artery bypass surgery (CABG) is associated with long-term survival benefits1-3. 3 
However, less is known about the potential benefit of a third arterial conduit.  4 
To date, the studies that have compared the long-term survival of CABG patients receiving two 5 
vs. three arterial conduits have reported conflicting results4-11. However, all of these studies 6 
come from single centers and have limited sample size. It is highly likely that the potential 7 
additional survival benefit of a third arterial conduit is less when compared to that of a second, 8 
making it plausible that single institutional studies are underpowered to detect moderate 9 
differences in survival.  10 
In order to overcome this limitation and to provide the best available evidence on this topic, we 11 
present a meta-analysis of propensity score matched (PSM) observational studies that 12 
compared the long-term outcomes of CABG in patients who received two vs. three arterial 13 
grafts. 14 
15 
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Methods 1 
Search Strategy and Selection of Studies 2 
This systematic review was conducted according to the Preferred Reporting Items for 3 
Systematic Reviews and Meta-Analyses (PRISMA) guidelines12.  4 
In August 2016, a literature search using MEDLINE, EMBASE, and Web of Science to identify 5 
relevant articles was performed. Observational studies included in the present meta-analysis 6 
met the following criteria: (1) patients undergoing first time isolated CABG; (2) comparison of 7 
long-term survival of patients receiving two arterial conduits (2-ART) vs. patients receiving 8 
three arterial conduits (3-ART); and (3) PSM was used to account for non-random allocation to 9 
treatment (2-ART vs. 3-ART). Non-English language, review articles, case reports, and editorials 10 
were excluded. Search terms used the controlled vocabularies of MEDLINE and EMBASE alone 11 
or in combination with text words including ‘‘third arterial conduit CABG’’, “third arterial graft 12 
CABG’’, ‘‘total arterial revascularization CABG’’, ‘‘propensity score’’, and ‘‘propensity score 13 
matching’’. Two reviewers (M.G. and A.D.F.) independently reviewed the titles and abstracts to 14 
determine whether the study met the inclusion criteria. In the case of disagreement, an 15 
agreement was negotiated. In the case of several publications with overlapping study 16 
populations, the largest sample size study with longest follow-up available was selected.  17 
We assessed the quality of included studies with the Newcastle-Ottawa Scale for observational 18 
studies13. The highest possible score is 9 stars, and the quality is graded as low level (<6 stars) 19 
or high level (≥6 stars).  20 
 21 
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Data Extraction  1 
Microsoft Office Excel 2010 (Microsoft, Redmond, Wash) was used for data extraction that was 2 
performed independently by 2 researchers (A.D.F. and L.B.O.). In the case of initial 3 
disagreement, an agreement was negotiated. Where additional information was deemed 4 
necessary, the corresponding author of the relevant study was contacted directly. Study design, 5 
study period, country, and center where the study was conducted, unmatched and matched 6 
sample size, type of arterial conduits, PSM methods, completeness of follow-up, and follow-up 7 
duration were documented. The following patient characteristics in the unmatched and 8 
matched groups were also registered: age, female sex, diabetes mellitus, reduced left 9 
ventricular ejection fraction (as defined by the authors), chronic obstructive pulmonary disease, 10 
renal impairment (as defined by the authors), target vessels, and predicted operative risk 11 
according to the EuroSCORE or the Society of Thoracic Surgeons score14. 12 
The primary endpoint was long-term mortality in the matched populations. Secondary 13 
endpoints were in-hospital/30-day mortality for the matched populations and long-term 14 
mortality in the unmatched populations. In the matched population, time-to-event outcome for 15 
long-term mortality was extracted as hazard ratios (HRs) along with their variance.  16 
Statistical Analysis 17 
Continuous variables are reported as median (25th, 75th percentile) or as mean±standard 18 
deviation. Categorical variables are expressed as (%). Statistical pooling of survival, time-to-19 
event, was performed according to a random-effect model, computing risk estimates with 95% 20 
confidence intervals (CI), using RevMan 5 (The Cochrane Collaboration, The Nordic Cochrane 21 
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Centre and Copenhagen, Denmark). From one study we derived the incidence of all-cause 1 
mortality from a Kaplan-Meier survival curve using a described method15. Study bias was 2 
appraised by graphical inspection of funnel plots, and Egger’s linear regression method was 3 
used to quantify the bias. Hypothesis testing for equivalence was set at the two-tailed 0.05 4 
level. Hypothesis testing for statistical homogeneity was set at the two-tailed 0.10 level and was 5 
based on the Cochran Q test, with I2 values of 25%, 50%, and 75% representing mild, moderate, 6 
and severe heterogeneity, respectively. Meta-regression analysis and the “one study removed 7 
analysis” were performed with Comprehensive Meta-Analysis, reporting results as regression 8 
coefficient (i.e. Beta). 9 
10 
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Results 1 
Selected Studies 2 
From 201 abstracts, 21 full-text articles fitting the relevant selection criteria were selected. 3 
After evaluating the full-text articles, 13 observational studies that did not perform PSM 4 
adjusted comparison between patients receiving two vs three arterial conduits16-28 were 5 
excluded. A total of 8 PSM studies were finally selected for the systematic review and meta-6 
analysis4-11. An outline of the systematic review process is depicted in Figure 1. An overview of 7 
the PSM studies is summarized in Tables 1 and 2 (variables included for PSM are summarized in 8 
Supplementary Table 1). Overall, selected studies reported on 10,287 matched patients (2-ART, 9 
5346; 3-ART, 4941) for final comparisons. PSM populations presented a similar preoperative 10 
risk factor distribution in the 2-ART and 3-ART groups (Table 3).  11 
Early Mortality 12 
All studies except for three5,6,8 reported on comparisons of in-hospital/30-day mortality for the 13 
PSM series (different definitions were adopted, see Table 1). Glineur et al. did not report any 14 
data on in-hospital/30-day mortality and two other studies, Locker et al. and Di Mauro et al., 15 
reported overall mortality without distinguishing between the 2-ART and 3-ART groups. In-16 
hospital/30-day mortality ranged from 0.4% to 2.7% and 0.3% to 2.9% in the 2-ART and 3-ART 17 
groups, respectively. Pooled estimates showed no significant difference between the two 18 
groups (HR: 0.93; 95% CI, 0.71-1.22; p= .62; Figure 2). Meta-regression analysis showed neither 19 
female sex (Beta -0.13 [CI -0.02; +1.75], p= .89) nor diabetes affected early outcome (Beta -0.14 20 
[CI -1-47; +1.19], p= .83). 21 
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Long-Term Mortality  1 
All studies reported the comparison of long-term mortality for the PSM series. However, Nasso 2 
et al.10 reported survival in a Kaplan Meier survival curve. In this study the HR for long-term 3 
mortality was then derived from the Kaplan Meier as described in the Methods section. In the 4 
study by Di Mauro et al.5 the HR for the 2-ART and 3-ART groups could not be calculated and 5 
this study was omitted from the final analysis.  6 
The mean follow-up time ranged from 37.2 to 196.8 months (Table 2). The use of three arterial 7 
grafts was associated with a statistically significant reduction of late death when compared with 8 
the use of two arterial conduits (HR: 0.8; 95%CI, 0.75-0.87; p< .001; Figure 3). This result was 9 
confirmed in the studies4,6,8,11 that reported the late mortality in the unmatched population 10 
(HR: 0.57; 95% CI, 0.33-0.98; p= .04; Figure 4). The leave-one-out analysis confirmed these 11 
results (Figure 5). 12 
Meta-regression analysis showed neither female sex (Beta 0.13 [-0.23; +0.5), p= .47) nor 13 
diabetes affected long-term survival (Beta 0.19 [CI -0.23; +0.64], p= .4). 14 
Publication Bias and internal validity appraisal 15 
The Newcastle-Ottawa Scale confirmed a high-quality level for all PSM studies included in the 16 
main analysis (Supplementary Table 2). Heterogeneity for PSM analysis was high for long-term 17 
(I2= 58.8%) and for 30-day mortality (I2= 85.6%), and extensive in the overall population analysis 18 
(I2= 91.3%). No significant publication bias was found, as confirmed by Egger’s test 19 
(Supplementary Figures 1 and 2).  20 
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Discussion 1 
Even in the absence of randomized controlled trials (RCTs), the clinical benefits related to the 2 
use of two arterial grafts at the time of CABG are strongly supported by abundant 3 
circumstantial evidence. In 1999 the Cleveland Clinic investigators were among the first to 4 
report a clear survival advantage for patients receiving bilateral internal thoracic artery (BITA) 5 
instead of single internal thoracic artery (SITA) grafts29. Since that seminal paper, a substantial 6 
amount of observational evidence has reported better clinical outcomes with the use of two vs. 7 
one arterial grafts for CABG patients. 8 
Most recently, the 5-year interim analysis of the ART trial that randomized 3,102 patients to 9 
receive SITA or BITA showed similar mortality, myocardial infraction and stroke30. There are 10 
several possible explanations for the similar outcomes. First, the failure rate of saphenous vein 11 
is known to be relatively low for the first 5 years after CABG but then increases.   Second, very 12 
high use of guideline based medical therapy with almost 90% of the patients receiving aspirin 13 
and statins and almost three quarters on beta-blockers and ACE inhibitors, may have reduced 14 
the risk of development of disease and failure of vein grafts. Third, the simultaneous use of a 15 
radial artery (with its proven superior angiographic patency in comparison to vein grafts at 5 16 
years31) in 20% of the SITA group may also have resulted in a narrowing of differences in mid-17 
term outcome.  A further possibility is that while the addition of a second ITA graft makes no 18 
difference to 5-year survival, this may change over the longer-term as there is a marked 19 
difference in angiographic patency between ITA and vein grafts after 10 years32.  20 
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While awaiting the 10-year outcomes of ART, current available evidence suggests that the use 1 
of two arterial grafts for CABG is associated with significantly better outcome. Indeed, in a 2 
meta-analysis of over 15,000 patients receiving SITA or BITA followed for a mean of over 9 3 
years, the Oxford group reported a 22% survival benefit for those receiving two arterial 4 
conduits (HR: 0.78; CI, 0.72–0.84; p< .0001)33. Similarly, in the only meta-analysis that 5 
compared clinical outcomes of patients receiving either a radial artery or a saphenous vein as 6 
the second graft, Zhang and coauthors found a significantly lower incidence of cardiac death, 7 
myocardial infarction, and repeat coronary procedures in the arterial group (OR: 0.72, 0.68, and 8 
0.27 respectively)34. 9 
The benefits related to the addition of a third arterial conduit are much more controversial. The 10 
few studies that have directly compared the outcomes of patients receiving two vs. three 11 
arterial grafts have reported conflicting results.  Di Mauro et al., analyzing a cohort of 885 12 
patients with BITA to the left coronary artery system, described increased mortality and 13 
cardiac-death rates when the gastroepiploic artery instead of the saphenous vein was used to 14 
graft the right coronary artery5. Similarly, Nasso and associates found no additional clinical 15 
benefits with the addition of a third arterial graft in a large cohort of 10,752 CABG patients10. In 16 
addition, Benedetto et al. and Mohammadi et al. found that using the radial artery or the 17 
saphenous vein in addition to BITA did not improve long-term outcomes4,9. 18 
On the other hand, the Mayo Clinic group reported improved late survival with the use of three 19 
arterial conduits8 and Glineur et al. had superior outcomes using the gastroepiploic artery, 20 
instead of a saphenous vein, to complement the two ITAs6. Both Grau and Shi and coauthors, in 21 
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two large propensity matched series, reported a significant survival benefit for patients who 1 
received three vs. two arterial conduits7,11. 2 
One possible reason for these contradictory findings is that the survival benefit provided by the 3 
use of a third arterial graft is lower when compared to the use of the first or second arterial 4 
conduit. Consequently, in view of their relatively small individual populations, most of the single 5 
institutional studies were underpowered to detect moderate differences in survival. The 6 
present study was meant to overcome this potential limitation by using a meta-analytic 7 
approach.   8 
Even though meta-analyses of PSM studies are not as methodologically robust as meta-analyses 9 
of RCTs, they are emerging as an attractive alternative. In view of the paucity of evidence from 10 
RCTs in the surgical literature, the meta-analytic approach based on PSM studies can be relied 11 
on as evidence when RCTs are not possible or not available35.  12 
Our analysis pooled data from 10,287 matched patients receiving two vs. three arterial 13 
conduits. Our main finding is that the use of a third arterial graft is not associated with an 14 
increase in the operative risk but rather with a 24% survival benefit at a mean follow-up of 77.9 15 
months. This survival advantage is independent of the patient’s sex and diabetic status. 16 
The most likely explanation for these findings is the demonstrated lower attrition rate of 17 
arterial grafts. All the studies that have compared the angiographic patency of arterial vs. 18 
venous bypass grafts have consistently shown a better patency rate for the former, with the 19 
difference in patency increasing with the length of the follow-up31,36.  20 
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Indeed, we have recently described how 20 years after CABG the risk of graft failure for the 1 
venous grafts is almost three times higher than that of arterial conduits32. An additional 2 
potential contributor to the improved outcomes of patients who received three arteries is 3 
probably the protective effect of arterial grafts against the development of atherosclerotic 4 
disease in the native coronary circulation37.   5 
Unfortunately, the available data do not allow a further analysis of eventual survival differences 6 
related to the location of the third arterial conduit on the left or right coronary system or the 7 
type of graft configuration used. These are important points that require further investigation. 8 
It is important to note that in the US only 6% of the patients undergoing primary isolated CABG 9 
receive more than one arterial graft38. A similar situation exists in Europe and in Asia38,39. Even 10 
in the absence of global data, the current literature suggests that the proportion of patients 11 
receiving a second arterial conduit at the time of CABG worldwide is in the 15-20% range. 12 
The reasons for this underuse of arterial grafts are complex and multifactorial. The increasing 13 
complexity of the population of patients referred for CABG, but also the increasing pressure 14 
toward higher surgical “productivity” and the importance of short-term “quality metrics”, such 15 
as the avoidance of sternal complications, are possible explanations. 16 
Limitations 17 
The present analysis has intrinsic limitations. First, any matching system can only adjust for 18 
measurable and included variables. It is likely that while selecting which patients should receive 19 
three arterial grafts the operating surgeons relied on an immeasurable, but reliable, “eye-20 
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balling” that comes from experience and cannot be neutralized by any statistical method. This 1 
means that healthier patients are more likely to have received three arterial conduits. 2 
Secondly, propensity matching by definition increases internal validity at the expense of 3 
generalizability. The fact that only about two thirds of the overall population was included in 4 
the matched comparison clearly limits the ability to extend our findings to the majority of CABG 5 
patients. 6 
Also, looking at Table 3, it is evident that the population of patients included in most of the 7 
examined studies is younger and in general healthier than that seen by most cardiac surgery 8 
centers in their everyday clinical practice. It is highly likely that this patients’ population 9 
represents a selected group of the totality of cases referred for CABG and it is possible that the 10 
described benefits associated with the use of a third arterial grafts does not apply to the 11 
generality of the CABG population. 12 
Moreover, not all the studies evaluated all the outcomes of interest, so we specified the 13 
number of the studies and of patients for each outcome; most of the results are based on very 14 
small numbers of deaths.  Group level analysis also introduced the problem of ecological bias 15 
for regression of ecologic variables such as sex or diabetes, potentially failing to detect these 16 
interactions40. 17 
Finally, the different authors used different grafting strategies and matching models so that the 18 
homogeneity of the included populations cannot be regarded as optimal.  19 
In conclusion, in a meta-analysis of the PSM studies comparing the use of two vs. three arterial 20 
grafts for CABG, we found that the use of three arterial conduits is not associated with an 21 
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increase in the operative risk but is associated with a statistically significant survival benefit at 1 
long-term follow-up. These finding support the concepts that complete revascularization and 2 
extensive use of arterial grafts should be the cornerstone of modern coronary artery surgery. 3 
  13
Acknowledgments 1 
There are no acknowledgments for this paper. 2 
3 
  14
Sources of Funding 1 
There were no sources of funding for this paper.2 
  15
Disclosures 1 
There are no disclosures for this paper. 2 
  16
References 
1. Weiss AJ, Zhao S, Tian DH, Taggart DP, Yan TD. A meta-analysis comparing bilateral 
internal mammary artery with left internal mammary artery for coronary artery bypass 
grafting. Ann Cardiothorac Surg. 2013;2:390–400. DOI: 10.3978/j.issn.2225-
319X.2013.07.16. 
2. Grau JB, Ferrari G, Mak AWC, Shaw RE, Brizzio ME, Mindich BP, Strobeck J, Zapolanski A. 
Propensity matched analysis of bilateral internal mammary artery versus single left 
internal mammary artery grafting at 17-year follow-up: validation of a contemporary 
surgical experience. Eur J Cardiothorac Surg. 2012;41:770–775. DOI: 
10.1093/ejcts/ezr213. 
3. Tranbaugh RF, Dimitrova KR, Friedmann P, Geller CM, Harris LJ, Stelzer P, Cohen BM, Ko 
W, DeCastro H, Lucido D, Hoffman DM. Coronary artery bypass grafting using the radial 
artery: clinical outcomes, patency, and need for reintervention. Circulation. 
2012;126:S170-175. DOI: 10.1161/CIRCULATIONAHA.111.083048. 
4. Benedetto U, Caputo M, Zakkar M, Bryan A, Angelini GD. Are three arteries better than 
two? Impact of using the radial artery in addition to bilateral internal thoracic artery 
grafting on long-term survival. J Thorac Cardiovasc Surg. 2016;152:862–869. DOI: 
10.1016/j.jtcvs.2016.04.054. 
5. Di Mauro M, Contini M, Iacò AL, Bivona A, Gagliardi M, Varone E, Bosco P, Calafiore AM. 
Bilateral internal thoracic artery on the left side: a propensity score-matched study of 
impact of the third conduit on the right side. J Thorac Cardiovasc Surg. 2009;137:869–
874. DOI: 10.1016/j.jtcvs.2008.09.014. 
  17
6. Glineur D. Importance of the third arterial graft in multiple arterial grafting strategies. 
Ann Cardiothorac Surg. 2013;2:475–480. DOI: 10.3978/j.issn.2225-319X.2013.07.01. 
DOI: 10.3978/j.issn.2225-319X.2013.07.01. 
7. Grau JB, Kuschner CE, Johnson CK, Ferrari G, Zapolanski A, Brizzio ME, Shaw RE. The 
effects of using a radial artery in patients already receiving bilateral internal mammary 
arteries during coronary bypass grafting: 30-day outcomes and 14-year survival in a 
propensity-matched cohort. Eur J Cardiothorac Surg. 2016;49:203–210. DOI: 
10.1093/ejcts/ezv176. 
8. Locker C, Schaff HV, Dearani JA, Joyce LD, Park SJ, Burkhart HM, Suri RM, Greason KL, 
Stulak JM, Li Z, Daly RC. Multiple arterial grafts improve late survival of patients 
undergoing coronary artery bypass graft surgery: analysis of 8622 patients with 
multivessel disease. Circulation. 2012;126:1023–1030. DOI: 
10.1161/CIRCULATIONAHA.111.084624. 
9. Mohammadi S, Dagenais F, Voisine P, Dumont E, Charbonneau E, Marzouk M, 
Paramythiotis A, Kalavrouziotis D. Impact of the Radial Artery as an Additional Arterial 
Conduit During In-Situ Bilateral Internal Mammary Artery Grafting: A Propensity Score-
Matched Study. Ann Thorac Surg. 2016;101:913–918. DOI: 
10.1016/j.athoracsur.2015.08.054. 
10. Nasso G, Popoff G, Lamarra M, Romano V, Coppola R, Bartolomucci F, Giglio MD, Romeo 
F, Tavazzi L, Speziale G. Impact of arterial revascularization in patients undergoing 
coronary bypass. J Card Surg. 2012;27:427–433. DOI: 10.1111/j.1540-
8191.2012.01481.x. 
  18
11. Shi WY, Tatoulis J, Newcomb AE, Rosalion A, Fuller JA, Buxton BF. Is a third arterial 
conduit necessary? Comparison of the radial artery and saphenous vein in patients 
receiving bilateral internal thoracic arteries for triple vessel coronary disease. Eur J 
Cardiothorac Surg. 2016;50:53–60. DOI: 10.1093/ejcts/ezv467. 
12. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for 
systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 
2009;6:e1000097. DOI: 10.1371/journal.pmed.1000097. 
13. Wells G, Shea B, O’Connel D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-
Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-
analyses. [webpage on the Internet] Ottawa, ON: Ottawa Hospital Research Institute; 
2011. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp 
14. Nilsson J, Algotsson L, Höglund P, Lührs C, Brandt J. Early mortality in coronary bypass 
surgery: the EuroSCORE versus The Society of Thoracic Surgeons risk algorithm. Ann 
Thorac Surg. 2004;77:1235-1239-1240. DOI: 10.1016/j.athoracsur.2003.08.034. 
15. Liu Z, Rich B, Hanley JA. Recovering the raw data behind a non-parametric survival 
curve. Syst Rev. 2014;3:151. DOI: 10.1186/2046-4053-3-151. 
16. Bisleri G, Di Bacco L, Giroletti L, Muneretto C. Total arterial grafting is associated with 
improved clinical outcomes compared to conventional myocardial revascularization at 
10 years follow-up. Heart Vessels. 2016; [Epub ahead of print]. DOI: 10.1007/s00380-
016-0846-6. 
17. Bortolussi G, Bejko J, Gallo M, Comisso M, Carrozzini M, Guglielmi C, Testolin L, Toscano 
G, Rubino M, Bianco R, Tarzia V, Gerosa G, Bottio T. Coronary Artery Bypass Grafting in 
  19
Elderly Patients: Insights from a Comparative Analysis of Total Arterial and Conventional 
Revascularization. J Cardiovasc Transl Res. 2016;9:223–229. DOI: 10.1007/s12265-016-
9688-y. 
18. Buxton BF, Shi WY, Tatoulis J, Fuller JA, Rosalion A, Hayward PA. Total arterial 
revascularization with internal thoracic and radial artery grafts in triple-vessel coronary 
artery disease is associated with improved survival. J Thorac Cardiovasc Surg. 
2014;148:1238-1243-1244. DOI: 10.1016/j.jtcvs.2014.06.056. 
19. Choi J-S, Cho KR, Kim K-B. Does diabetes affect the postoperative outcomes after total 
arterial off-pump coronary bypass surgery in multivessel disease? Ann Thorac Surg. 
2005;80:1353–1360. DOI: 10.1016/j.athoracsur.2005.04.026. 
20. Formica F, Ferro O, Greco P, Martino A, Gastaldi D, Paolini G. Long-term follow-up of 
total arterial myocardial revascularization using exclusively pedicle bilateral internal 
thoracic artery and right gastroepiploic artery. Eur J Cardiothorac Surg. 2004;26:1141–
1148. DOI: 10.1016/j.ejcts.2004.08.027. 
21. Hirose H, Amano A, Takahashi A. Triple arterial coronary revascularization using the 
radial artery and bilateral internal mammary arteries versus the gastroepiploic artery 
and bilateral internal mammary arteries. Circ J. 2002;66:544–548. 
22. Muneretto C, Bisleri G, Negri A, Manfredi J, Metra M, Nodari S, Culot L, Dei Cas L. Total 
arterial myocardial revascularization with composite grafts improves results of coronary 
surgery in elderly: a prospective randomized comparison with conventional coronary 
artery bypass surgery. Circulation. 2003;108 Suppl 1:II29-33. DOI: 
10.1161/01.cir.0000087941.75337.f5. 
  20
23. Muneretto C, Negri A, Bisleri G, Manfredi J, Terrini A, Metra M, Nodari S, Cas LD. Is total 
arterial myocardial revascularization with composite grafts a safe and useful procedure 
in the elderly? Eur J Cardiothorac Surg. 2003;23:657–664. 
24. Muneretto C, Bisleri G, Negri A, Piccoli P, Nodari S, Dei Cas L. Improved graft patency 
rates and mid-term outcome of diabetic patients undergoing total arterial myocardial 
revascularization. Heart Int. 2006;2:136. DOI: 10.4081/hi.2006.136. 
25. Shi WY, Hayward PA, Tatoulis J, Rosalion A, Newcomb AE, Fuller JA, Buxton BF. Are all 
forms of total arterial revascularization equal? A comparison of single versus bilateral 
internal thoracic artery grafting strategies. J Thorac Cardiovasc Surg. 2015;150:1526–
1533, 1534-3-1534. DOI: 10.1016/j.jtcvs.2015.05.074. 
26. Suzuki T, Asai T, Kinoshita T. Total arterial off-pump coronary artery bypass grafting was 
not associated with inferior outcomes for diabetic when compared with non-diabetic 
patients. Interact Cardiovasc Thorac Surg. 2015;21:705–711. DOI: 10.1093/icvts/ivv234. 
27. Tatoulis J, Wynne R, Skillington PD, Buxton BF. Total Arterial Revascularization: 
Achievable and Prognostically Effective-A Multicenter Analysis. Ann Thorac Surg. 
2015;100:1268–1275. DOI: 10.1016/j.athoracsur.2015.03.107. 
28. Tatoulis J, Wynne R, Skillington PD, Buxton BF. Total Arterial Revascularization: A 
Superior Strategy for Diabetic Patients Who Require Coronary Surgery. Ann Thorac Surg. 
2016; [Epub ahead of print]. DOI: 10.1016/j.athoracsur.2016.05.062. 
29. Lytle BW, Blackstone EH, Loop FD, Houghtaling PL, Arnold JH, Akhrass R, McCarthy PM, 
Cosgrove DM. Two internal thoracic artery grafts are better than one. J Thorac 
Cardiovasc Surg. 1999;117:855–872. DOI: 10.1016/S0022-5223(99)70365-X. 
  21
30. Taggart DP, Altman DG, Gray AM, Lees B, Gerry S, Benedetto U and Flather M for the 
ART Investigators. Randomized trial of Bilateral versus Single Internal-Thoracic-Artery 
Grafts. N Engl J Med. 2016 Nov 14 [E-pub ahead of print]; DOI: 
10.1056/NEJMoa1610021. 
31. Deb S, Cohen EA, Singh SK, Une D, Laupacis A, Fremes SE, RAPS Investigators. Radial 
artery and saphenous vein patency more than 5 years after coronary artery bypass 
surgery: results from RAPS (Radial Artery Patency Study). J Am Coll Cardiol. 2012;60:28–
35. DOI: 10.1016/j.jacc.2012.03.037. 
32. Gaudino M, Tondi P, Benedetto U, Milazzo V, Flore R, Glieca F, Ponziani FR, Luciani N, 
Girardi LN, Crea F, Massetti M. Radial Artery as a Coronary Artery Bypass Conduit: 20-
Year Results. J Am Coll Cardiol. 2016;68:603–610. DOI: 10.1016/j.jacc.2016.05.062. 
33. Yi G, Shine B, Rehman SM, Altman DG, Taggart DP. Effect of bilateral internal mammary 
artery grafts on long-term survival: a meta-analysis approach. Circulation. 
2014;130:539–545. DOI: 10.1161/CIRCULATIONAHA.113.004255. 
34. Zhang H, Wang ZW, Wu HB, Hu XP, Zhou Z, Xu P. Radial artery graft vs. saphenous vein 
graft for coronary artery bypass surgery: which conduit offers better efficacy? Herz. 
2014;39:458–465. DOI: 10.1007/s00059-013-3848-5. 
35. Lonjon G, Boutron I, Trinquart L, Ahmad N, Aim F, Nizard R, Ravaud P. Comparison of 
treatment effect estimates from prospective nonrandomized studies with propensity 
score analysis and randomized controlled trials of surgical procedures. Ann Surg. 
2014;259:18–25. DOI: 10.1097/SLA.0000000000000256. 
  22
36. Hayward PAR, Hare DL, Gordon I, Buxton BF. Effect of radial artery or saphenous vein 
conduit for the second graft on 6-year clinical outcome after coronary artery bypass 
grafting. Results of a randomised trial. Eur J Cardiothorac Surg. 2008;34:113–117. DOI: 
10.1016/j.ejcts.2008.03.027. 
37. Dimitrova KR, Hoffman DM, Geller CM, Dincheva G, Ko W, Tranbaugh RF. Arterial grafts 
protect the native coronary vessels from atherosclerotic disease progression. Ann 
Thorac Surg. 2012;94:475–481. DOI: 10.1016/j.athoracsur.2012.04.035. 
38. Kurlansky P. The data and use of bilateral internal thoracic artery grafting: a paradox 
indeed. J Thorac Cardiovasc Surg. 2015;149: 848-849. DOI: 10.1016/j.jtcvs.2014.11.084 
39. Yan BP, Clark DJ, Buxton B, Ajani AE, Smith JA, Duffy SJ, Shardey GC, Skillington PD, 
Farouque O, Yii M, Yap CH, Andrianopoulos N, Brennan A, Dinh D, Reid CM; Australasian 
Society of Cardiac and Thoracic Surgeons (ASCTS); Melbourne Interventional Group 
(MIG). Clinical characteristics and early mortality of patients undergoing coronary artery 
bypass grafting compared to percutaneous coronary intervention: insights from the 
Australasian Society of Cardiac and Thoracic Surgeons (ASCTS) and the Melbourne 
Interventional Group (MIG) Registries. Heart Lung Circ. 2009;18:184-90. DOI: 
10.1016/j.hlc.2008.10.005. 
40. Berlin JA, Santanna J, Schmid CH, Szczech LA, Feldman HI; Anti-Lymphocyte Antibody 
Induction Therapy Study Group. Individual patient- versus group-level data meta-
regressions for the investigation of treatment effect modifiers: ecological bias rears its 
ugly head. Stat Med. 2002;21:371-87. 
  23
Figure Legends 
Figure 1. Flow chart for study selection. 
Figure 2. Forest plot comparing the effect of the use of three arterial conduits (3-ART) vs. two 
arterial conduits (2-ART) on in-hospital/30-day mortality across individual propensity score-
matched studies. CI, confidence interval (5 studies including 9106 patients). 
Figure 3. Forest plot comparing the effect of the use of three arterial conduits (3-ART) vs. two 
arterial conduits (2-ART) on late mortality across individual propensity score-matched studies. 
CI, confidence interval. (7 studies including 9402 patients). 
Figure 4. Forest plot comparing the effect of the use of three arterial conduits (3-ART) vs. two 
arterial conduits (2-ART) on late mortality across individual unmatched studies. CI, confidence 
interval. (4 studies including 3742 patients). 
Figure 5. Forest plot of the leave-one-out analysis comparing the effect of the use of three 
arterial conduits (3-ART) vs. two arterial conduits (2-ART) on late mortality. CI, confidence 
interval.  
Supplementay Figure 1. Funnel plot comparing the effect of the use of three arterial conduits 
(3-ART) vs. two arterial conduits (2-ART) on late mortality across individual propensity score-
matched studies. 
Supplementay Figure 2. Funnel plot comparing the effect of the use of three arterial conduits 
(3-ART) vs. two arterial conduits (2-ART) on in-hospital/30-day mortality across individual 
propensity score-matched studies. 
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Table 1. Overview of propensity score-matching studies included in the primary analysis 
Study Year  Country Centers 
Study 
period 
Conduits    
2-ART 
Conduits  
3-ART PSM Methodology 
SV target  
(2-ART UNM) 
Outcomes of interest 
reported (PSM populations) 
Benedetto4 2016 United 
Kingdom 
Bristol Heart 
Institute 
1996- 2015 BITA-GSV BITA-RA Greedy 1:1 matching 
with caliber width of 
0.2 SD 
CX, DIA, RCA In-hospital mortality.  
All-cause late mortality. 
Di Mauro5 2008 Italy University of 
Chieti 
1991- 2002 BITA-GSV BITA-RA 
BITA-RGEA 
2:1 matching method 
not reported 
RCA Long-term death from any 
cause. 
Glineur6 2013 Belgium Cliniques 
Universitaire St 
Luc, Brussels 
1985- 1995 BITA-GSV BITA-RGEA Matching method not 
reported 
RCA Overall survival. 
 
Grau7 2015 United 
States 
The Valley 
Columbia Heart 
Center, 
Ridgewood, NJ.  
University of 
Pennsylvania, 
Philadelphia, PA 
2000-2013 BITA-GSV BITA-RA Greedy 1:1, 5-1 digit 
matching 
CX, LAD, RCA 30-day mortality.  
Long-term survival. 
Locker8 2012 United 
States 
Mayo Clinic, 
Rochester, MN 
1993- 2009 BITA-GSV BITA-RA 1:1 matching method 
not reported 
CX, DIA, RCA Late death: after 30 days. 
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Mohammadi9 2016 Canada Quebec Heart and 
Lung University 
Institute, Quebec 
City, Quebec 
1991- 2013 BITA-GSV BITA-RA 5-digit 1:1 matching 
without replacement 
CX, RCA Short-term (in-hospital) 
mortality.  
Long-term all-cause mortality. 
Nasso10 2012 Italy Anthea Hospital, 
GVM Care & 
Research, Bari 
2003-2008 BITA-GSV BITA-RA 1:1 matching nearest-
neighbor matching 
caliber width of ± 0.1 
CX, RCA Operative death: within 30 
days of the operation or 
before hospital discharge). 
Long-term mortality.  
Shi11 2016 Australia St. Vincent's 
Hospital, 
University of 
Melbourne,  
Melbourn 
1995- 2010 BITA-GSV BITA-RA Greedy 1:1 matching 
with fixed caliber width 
of 0.05 without 
replacement 
CX, RCA Short-term (30-day) mortality. 
Long-term survival.  
BITA, bilateral internal thoracic arteries; CX, circumflex coronary system; DIA, diagonal coronary artery; GSV, greater saphenous vein; LAD, left anterior descending artery; PSM, 
propensity score-matched; RA, radial artery; RCA, right coronary artery; RGEA, Right gastroepiploic artery; UNM, unmatched. 
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Table 2. Overview of propensity score-matching studies included in the primary analysis. 
Study 
Overall 
population, n 
UNM 
2-ART, n 
UNM 
3-ART, n 
PSM 
2-ART, n 
PSM 
3-ART, n 
Mean/median follow-up 
(months) 
Completeness 
of follow-up (%) 
PSM-HR for 
long-term mortality provided 
Benedetto4 764 489 275 275 275 2-ART= 126 ± 58.8 
3-ART= 126 ± 54 
100 Yes 
Di Mauro5 1015 643 372 590 295 2-ART= 88 
3-ART= 128 
100 No 
Glineur6 297 204 93 203 93 2-ART= 196.8 ± 74.4 
3-ART= 192 ± 64.8 
NR Yes 
Grau7 751 568 183 183 183 NR (max 14 years) 100 Yes 
Locker8 1184 1029 155 NR NR Mean: 91.2 ± 55.2  
Median: 87.6 
94 No 
Mohammadi9 1750 1495 255 249 249 2-ART= 97.8 (IQR, 0.03- 22.6) 
3-ART=97.2 (IQR, 0.02-17) 
100 Yes 
Nasso10 7767 NR NR 3584 3584 Mean: 37.2 98 No 
Shi11 1497 460 1037 262 262 2-ART= 144 ± 60 
3-ART= 144 ± 60 
100 No 
ART, arteries; HR, hazard ratio; IQR, inter-quartile range; NR, not reported; PSM, propensity score-matched; UNM, unmatched. 
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Table 3. Risk factor distribution in the matched populations in studies included in the primary analysis. 
 Matched 
Study Age (y) Mean±SD Female (%) DM (%) EF (%) COPD (%) CRF (%) STS score (%) EuroSCORE (%) 
Benedetto4         
2-ART NR 5.8 5.5 NR 2.5 0.7 NR NR 
3-ART NR 6.5 6.5 NR 2.9 0.4 NR NR 
Di Mauro5         
2-ART 62.6 ± 8.7 12.5 21.4 60.6 ± 12.8 5.1 0 NR 3.5 ± 2.9 
3-ART 62.1 ± 8.0 11.9 20.7 59.5 ± 12.0 4.4 0.3 NR 3.1 ± 2.8 
Glineur6         
2-ART NR (quintiles) NR (quintiles) NR (quintiles) NR (quintiles) NR (quintiles) NR (quintiles) NR (quintiles) NR (quintiles) 
3-ART NR (quintiles) NR (quintiles) NR (quintiles) NR (quintiles) NR (quintiles) NR (quintiles) NR (quintiles) NR (quintiles) 
Grau7         
2-ART 58 ± 9 6.6 5.5 53 ± 11 2.2 0 0.8 NR 
3-ART 57 ± 10 7.7 6.0 52 ± 10 2.7 0 0.8 NR 
Locker8         
2-ART NR NR NR NR NR NR NR NR 
3-ART NR NR NR NR NR NR NR NR 
Mohammadi9         
2-ART 55.8±8.9 11.2 13.7 57.9±12.8 6.8 1.6 11.2 11.2 
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3-ART 56.1±8.9 9.6 12.1 59.9±12.5 4.4 2.4 9.6 9.6 
Nasso10         
2-ART 67.3 ± 9.3 20.4 48.2 NR (ranges) 9.9 NR NR NR (ranges) 
3-ART 67.1 ± 9 20.1 48.0 NR (ranges) 10.0 NR NR NR (ranges) 
Shi11         
2-ART NR (ranges) 9 13 NR (ranges) NR 0 NR NR 
3-ART NR (ranges) 10 13 NR (ranges) NR 1 NR NR 
COPD, chronic obstructive pulmonary disease; CRF, chronic renal failure (different definitions adopted); DM, diabetes mellitus; EF, ejection fraction; NR, not reported; SD, standard deviation; STS, 
Society of Thoracic Surgeons score. 
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